What is the current Quetiapine market size?

The Quetiapine market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Quetiapine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Quetiapine market?

Increasing demand for antipsychotic medications drives the Quetiapine market.

What challenges does the Quetiapine market face?

Patent expirations and generic competition pose challenges to the Quetiapine market.

Which regions lead the Quetiapine market?

North America and Europe are the leading regions in the Quetiapine market.

Who are the top companies in the Quetiapine market?

AstraZeneca and Teva Pharmaceutical are top companies in the Quetiapine market.

What future opportunities exist in the Quetiapine market?

Emerging markets and new indications offer future opportunities for the Quetiapine market.

How does technology impact the Quetiapine market?

Advances in drug delivery technology improve Quetiapine formulations and patient outcomes.

What is the regulatory landscape for the Quetiapine market?

Stringent regulations and FDA approvals shape the Quetiapine market future outlook.

What is the future outlook for the Quetiapine market?

The Quetiapine market is expected to experience steady growth due to increasing demand.

Quetiapine Market Intelligence Report 2026 — Updated June 2026

Quetiapine by Application (Adult, Old Man, Children And Adolescents), by Types (Immediate Release Tablets, Extended Release Tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Quetiapine Market Size | CAGR 4.2 Forecast 2033

Quetiapine Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Quetiapine Market Overview

The Quetiapine market refers to the global market for Quetiapine, an atypical antipsychotic medication used to treat various mental health conditions. As a key player in the psychopharmacology industry, the Quetiapine market size is estimated to be around $4.5 billion in 2025. The Quetiapine market growth outlook is expected to be positive, with a market forecast indicating a compound annual growth rate (CAGR) of 4-5% during the forecast period. The industry expansion is driven by increasing demand for effective treatments for mental health disorders, and the Quetiapine market is expected to experience significant growth due to its efficacy and safety profile.

Loading chart…

The Quetiapine market is driven by several key forces, including technology shifts towards more efficient and effective treatments, regulations governing the use of antipsychotic medications, and consumer behavior demanding more personalized and targeted therapies. The largest region for Quetiapine is North America, while the fastest-growing region is Asia-Pacific, driven by increasing awareness and demand for mental health treatments. The Quetiapine market is expected to experience significant growth during the forecast period, driven by the increasing prevalence of mental health disorders and the growing demand for effective treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	17.79 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Intas Pharmaceuticals; TAPI; Accord Healthcare; Hexal (Sandoz); Dr. Reddy's Laboratories; Lupin; Sun Pharmaceutical Industries; Hunan Dongting Pharmaceutical; SuZhou NO.4 Pharmaceutical Factory; Fuan Pharmaceutical; Zhejiang Supor Pharmaceuticals; Zhejiang Huahai Pharmaceutical; Hunan Dongting Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Quetiapine market is poised for significant growth, driven by various factors. The market dynamics are influenced by a combination of growth drivers, restraints, opportunities, and challenges that shape the Quetiapine market size and growth forecast.

Growth Drivers2 items

Increasing prevalence of mental health disorders, such as schizophrenia and bipolar disorder, is driving the demand for Quetiapine. This growth is further accelerated by the rising awareness about mental health and the availability of effective treatments.

Advancements in pharmaceutical technology have enabled the development of extended-release formulations and combination therapies, expanding the Quetiapine market and providing patients with more treatment options.

Restraints2 items

Stringent regulatory requirements and intense competition among generic drug manufacturers are limiting the growth of the Quetiapine market. These factors are affecting the pricing and profitability of Quetiapine products.

Side effects associated with Quetiapine, such as weight gain and increased risk of diabetes, are prompting patients to opt for alternative treatments, thereby constraining market growth.

Opportunities2 items

The growing demand for personalized medicine and telepsychiatry services presents opportunities for Quetiapine manufacturers to develop targeted therapies and online treatment platforms, enhancing patient engagement and outcomes.

Emerging markets, such as Asia-Pacific and Latin America, offer significant growth potential for the Quetiapine market due to their large and increasing patient populations, rising healthcare expenditure, and improving healthcare infrastructure.

Challenges2 items

The Quetiapine market faces challenges from the increasing adoption of alternative therapies, such as psychotherapy and lifestyle modifications, which can reduce the demand for pharmaceutical treatments.

Fluctuations in global economic conditions and trade policies can impact the supply chain, pricing, and availability of Quetiapine, affecting the overall growth forecast of the market.

Market Segmentation

Loading chart…

The Quetiapine segmentation by application is a crucial aspect of the market, as it determines the size and growth prospects of each segment. The Quetiapine market can be segmented into various applications, including treatment of schizophrenia, treatment of bipolar disorder, and treatment of major depressive disorder. Each of these applications contributes to the overall Quetiapine market size, with the treatment of schizophrenia being the largest segment. The application segment is expected to drive the growth of the Quetiapine market, with the increasing prevalence of mental health disorders and the rising demand for effective treatment options.

The Quetiapine market can also be segmented by types, including immediate-release and extended-release formulations. The immediate-release formulation is further sub-segmented into quetiapine fumarate and quetiapine hemifumarate, while the extended-release formulation is sub-segmented into quetiapine fumarate extended-release and quetiapine hemifumarate extended-release. Each of these sub-segments has its own unique characteristics, advantages, and disadvantages, and contributes to the overall Quetiapine market size. Understanding the market taxonomy of Quetiapine is essential to develop effective marketing strategies and to identify new business opportunities.

Quetiapine Segmentation Breakdown7 items

Application

Adult

Old Man

Children And Adolescents

Types

Immediate Release Tablets

Extended Release Tablets

Regional Insights

Loading chart…

The Quetiapine market growth is expected to vary across regions, with Asia Pacific emerging as the largest region, accounting for approximately 35% of the global market, driven by increasing adoption of Quetiapine, favorable policies, and significant investments in healthcare infrastructure. The fastest-growing region is anticipated to be Latin America, driven by rising demographics and improving ecosystem maturity.

In North America, key drivers include high adoption rates, well-established infrastructure, and a mature ecosystem. Europe is driven by favorable policies, significant investments, and a strong pharmaceutical industry. Asia Pacific is driven by large demographics, increasing adoption, and rising healthcare spending. Latin America is driven by growing demographics, improving infrastructure, and increasing healthcare access. Middle East & Africa is driven by rising demographics, increasing adoption, and growing healthcare investments.

The regional forecast indicates that Asia Pacific will continue to dominate the Quetiapine market, driven by Quetiapine market growth in countries such as China and India. Latin America is expected to experience rapid growth, driven by increasing adoption and improving ecosystem maturity.

Competitive Landscape

The Quetiapine market exhibits a moderately consolidated structure, with a mix of global players and local/regional companies driving competition. The Quetiapine competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to focus on premium pricing and strong distribution networks, while local companies often rely on competitive pricing and regional partnerships.

Companies in the Quetiapine market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must develop unique value propositions, leveraging technology, service models, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

AstraZeneca: regional expansion

Intas Pharmaceuticals: vertical integration

TAPI: premium pricing

Accord Healthcare: OEM tie-ups

Hexal (Sandoz): innovation pipeline

Dr. Reddy's Laboratories: local manufacturing

Key Quetiapine Companies13 items

AstraZeneca

Intas Pharmaceuticals

TAPI

Accord Healthcare

Hexal (Sandoz)

Dr. Reddy's Laboratories

Lupin

Sun Pharmaceutical Industries

Hunan Dongting Pharmaceutical

SuZhou NO.4 Pharmaceutical Factory

Fuan Pharmaceutical

Zhejiang Supor Pharmaceuticals

Zhejiang Huahai Pharmaceutical

Market Ecosystem

The Quetiapine ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Quetiapine, a prescription medication used to treat various mental health conditions. The ecosystem boundaries are defined by the interactions among these participants, influencing how value flows and is captured.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing Quetiapine formulations

Distributors / channel partners — delivering products to pharmacies

Service providers / after-sales — offering patient support services

End users / buyers — patients and healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

Data/analytics providers — supplying market insights and research

In the Quetiapine ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the approval and adoption of Quetiapine formulations. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards approvals. Switching costs and partnerships are also crucial, as they impact the ability of participants to adapt to changes in the ecosystem. Furthermore, the Quetiapine ecosystem differs by region, with varying regulatory requirements and market conditions. A thorough value chain analysis is necessary to understand these intricacies and navigate the complex Quetiapine ecosystem.

Recent Industry Insights

The Quetiapine industry trends have witnessed significant developments in the last 12-18 months. Recent partnerships between pharmaceutical companies have led to the expansion of Quetiapine's application in treating various mental health disorders. Notably, there have been strategic mergers and acquisitions that have enhanced the market presence of key players. Furthermore, the launch of new formulations and technologies has improved the efficacy and safety of Quetiapine-based treatments.

Additionally, regulatory changes have paved the way for increased accessibility to Quetiapine-based medications. A shift in consumer trends towards personalized medicine has also driven the demand for Quetiapine. The industry has seen notable funding rounds and expansions, with companies investing heavily in research and development to capitalize on emerging Quetiapine industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Quetiapine market. The Quetiapine market outlook is characterized by moderate attractiveness, driven by a growing demand for antipsychotic medications. However, the competitive intensity is high, with several established players in the market. The long-term outlook is positive, with opportunities for innovation in treatment-resistant conditions. The innovation landscape is evolving, with a focus on personalized medicine and novel formulations. The demand-supply balance is stable, but key risk factors include regulatory changes and patent expirations.

11 items

1. Executive Summary

2. Quetiapine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Quetiapine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Quetiapine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Adult

6.1.2. Old Man

6.1.3. Children And Adolescents

6.2. Global Quetiapine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immediate Release Tablets

6.2.2. Extended Release Tablets

6.3. Global Quetiapine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Quetiapine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Quetiapine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Quetiapine Market Competition by Key Manufacturers

8.1. Global Quetiapine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Quetiapine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AstraZeneca

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Intas Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. TAPI

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Accord Healthcare

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hexal (Sandoz)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dr. Reddy's Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Lupin

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sun Pharmaceutical Industries

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hunan Dongting Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SuZhou NO.4 Pharmaceutical Factory

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Fuan Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Zhejiang Supor Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Zhejiang Huahai Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Hunan Dongting Pharmaceutical

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Quetiapine Market

Figure 4: Global Quetiapine Market: Drivers

Figure 5: Global Quetiapine Market: Challenges

Figure 6: Global Quetiapine Market: Trends

Figure 7: Global Quetiapine Market: Opportunity

Figure 8: Global Quetiapine Market: Restraint

Figure 9: Global Quetiapine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Quetiapine Market Value (USD Million) By Region

Figure 15: Global Quetiapine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Quetiapine Market Value (USD Million) By Region

Figure 23: Global Quetiapine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Quetiapine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Quetiapine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Quetiapine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Quetiapine Market Value (USD Million) By Region

Table 10: Global Quetiapine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Quetiapine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Quetiapine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Quetiapine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AstraZeneca Basic Information And Sales Area

Table 31: AstraZeneca. Products Portfolio

Table 32: Intas Pharmaceuticals Basic Information And Sales Area

Table 33: Intas Pharmaceuticals. Products Portfolio

Table 34: TAPI Basic Information And Sales Area

Table 35: TAPI. Products Portfolio

Table 36: Accord Healthcare Basic Information And Sales Area

Table 37: Accord Healthcare. Products Portfolio

Table 38: Hexal (Sandoz) Basic Information And Sales Area

Table 39: Hexal (Sandoz). Products Portfolio

Table 40: Dr. Reddy's Laboratories Basic Information And Sales Area

Table 41: Dr. Reddy's Laboratories. Products Portfolio

Table 42: Lupin Basic Information And Sales Area

Table 43: Lupin. Products Portfolio

Table 44: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 45: Sun Pharmaceutical Industries. Products Portfolio

Table 46: Hunan Dongting Pharmaceutical Basic Information And Sales Area

Table 47: Hunan Dongting Pharmaceutical. Products Portfolio

Table 48: SuZhou NO.4 Pharmaceutical Factory Basic Information And Sales Area

Table 49: SuZhou NO.4 Pharmaceutical Factory. Products Portfolio

Table 50: Fuan Pharmaceutical Basic Information And Sales Area

Table 51: Fuan Pharmaceutical. Products Portfolio

Table 52: Zhejiang Supor Pharmaceuticals Basic Information And Sales Area

Table 53: Zhejiang Supor Pharmaceuticals. Products Portfolio

Table 54: Zhejiang Huahai Pharmaceutical Basic Information And Sales Area

Table 55: Zhejiang Huahai Pharmaceutical. Products Portfolio

Table 56: Hunan Dongting Pharmaceutical Basic Information And Sales Area

Table 57: Hunan Dongting Pharmaceutical. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Quetiapine Market Value (USD Million) By Region

Table 63: Global Quetiapine Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Quetiapine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	17.79 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Intas Pharmaceuticals; TAPI; Accord Healthcare; Hexal (Sandoz); Dr. Reddy's Laboratories; Lupin; Sun Pharmaceutical Industries; Hunan Dongting Pharmaceutical; SuZhou NO.4 Pharmaceutical Factory; Fuan Pharmaceutical; Zhejiang Supor Pharmaceuticals; Zhejiang Huahai Pharmaceutical; Hunan Dongting Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options